PREDICATE,SUBJECT_NAME,OBJECT_NAME,Factuality_Score,Cancer_Type,Category
DIAGNOSES,Biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Core needle biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Needle biopsy procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Sentinel Lymph Node Biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Genetic screening method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Fine needle aspiration biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Core needle biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Transbronchial lung biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Fine needle aspiration biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Needle biopsy procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mass Screening,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Mammography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
DIAGNOSES,Drill biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Excision biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Surgical biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mammography,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Imaging
DIAGNOSES,Xeromammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Excision biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Genetic Screening,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Doppler Ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Core needle biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Fine needle aspiration biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Excision biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Digital mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Genetic screening method,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Fine needle aspiration biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Excision biopsy,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,High Throughput Screening,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Core needle biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Incisional biopsy - action,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Core needle biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Fine needle aspiration biopsy,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Mammography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Imaging
DIAGNOSES,Fine needle aspiration biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Incisional biopsy - action,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Needle biopsy procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Fine needle aspiration biopsy,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Biopsy,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Mammography,Carcinoma in situ of breast,0.0,Female Breast Cancer,Imaging
DIAGNOSES,Mammography,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Imaging
DIAGNOSES,Screening Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Puncture biopsy,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Scintimammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Mammography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Imaging
DIAGNOSES,Sentinel Lymph Node Biopsy,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Liquid Biopsy,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Screening procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Sentinel Lymph Node Biopsy,Papillary carcinoma of the breast,0.0009990009990009,Female Breast Cancer,Biopsy
DIAGNOSES,peripheral blood profile,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Blood Tests
DIAGNOSES,Contrast enhanced spectral mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Color doppler ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Digital Mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Genetic screening method,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Digital Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Contrast-Enhanced Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Contrast-Enhanced Ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Image-Guided Biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Core needle biopsy,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Liquid Biopsy,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Core needle biopsy,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Biopsy,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Genetic screening method,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Sentinel Lymph Node Biopsy,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Screening Method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Ultrasound-Guided Core Biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,B mode ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Screening procedure,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Screening procedure,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Biopsy,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Vacuum assisted biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Excision biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Endoscopic biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Incisional biopsy - action,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Puncture biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Mammography,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Imaging
DIAGNOSES,Incisional biopsy - action,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Mammography,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Imaging
DIAGNOSES,Core needle biopsy,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Needle biopsy procedure,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Biopsy,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Core needle biopsy,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
MEASURES,Core needle biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Surgical biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Needle biopsy procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Mammography,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer,Imaging
DIAGNOSES,Mammography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Imaging
DIAGNOSES,Mammography,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Imaging
MEASURES,Fine needle aspiration biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Blood Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Blood Tests
MEASURES,Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
MEASURES,Core needle biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Liquid Biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Screening procedure,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Screening procedure,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Early Diagnosis
DIAGNOSES,MRI guided biopsy,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Contrast enhanced spectral mammography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
DIAGNOSES,Mammography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
DIAGNOSES,Liquid Biopsy,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasound guided biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Biopsy,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Biopsy
MEASURES,Contrast enhanced spectral mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Digital Mammography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
DIAGNOSES,Screening procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Genetic screening method,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Sentinel Lymph Node Biopsy,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Vacuum assisted biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy of lymph node using ultrasound guidance,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Imaging
DIAGNOSES,Core needle biopsy,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Screening procedure,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Contrast-Enhanced Mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Screening procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Scintimammography,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Imaging
MEASURES,Contrast-Enhanced Ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Color doppler ultrasound,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
DIAGNOSES,Bone marrow biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Excision biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Puncture biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fine needle aspiration biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Trucut biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Screening Examination,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Breast Imaging Reporting and Data System Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Digital mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Puncture biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Fine needle aspiration biopsy,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Core needle biopsy,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy of breast,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,High-Throughput Screening,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Liquid Biopsy,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Fine needle aspiration biopsy,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Screening for malignant neoplasm of lung,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Needle biopsy procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Screening procedure,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Ultrasound Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Mammography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Genetic screening method,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Needle biopsy procedure,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Xeromammography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
DIAGNOSES,Genetic screening method,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Endoscopic biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Orbital biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Film screen mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Doppler Ultrasound,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
MEASURES,Excision biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Surgical biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Muscle biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Doppler Ultrasound,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Imaging
DIAGNOSES,Surgical biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Digital mammography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
MEASURES,Core needle biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Biopsy,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
MEASURES,Digital mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
MEASURES,Mammography,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Imaging
DIAGNOSES,Biopsy of ovary,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Surgical biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Genetic screening method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Screening procedure,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Punch biopsy (procedure),Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Genetic screening method,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Ultrasound examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Positron Emission Mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Bone marrow biopsy,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Contrast enhanced spectral mammography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Biopsy,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Digital Mammography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
DIAGNOSES,Genetic screening method,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Core needle biopsy,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer,Biopsy
MEASURES,Mammography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
MEASURES,Contrast-Enhanced Mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Mass Screening,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Biopsy sampling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Needle biopsy procedure,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy of prostate,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Genetic screening method,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Early Diagnosis
DIAGNOSES,Excision biopsy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Needle biopsy procedure,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Biopsy,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Mammography,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Imaging
DIAGNOSES,Mammography,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Imaging
DIAGNOSES,Contrast-Enhanced Ultrasound,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
DIAGNOSES,Mammography,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Imaging
DIAGNOSES,Fine needle aspiration of breast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,MRI guided biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Contrast-Enhanced Ultrasound,Papillary carcinoma of the breast,0.0009990009990009,Female Breast Cancer,Imaging
DIAGNOSES,screening examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Biopsy of skin procedure,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Mammography,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Imaging
DIAGNOSES,Contrast-Enhanced Ultrasound,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer,Imaging
DIAGNOSES,Bone marrow biopsy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Genetic Screening,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Xeromammography,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Imaging
MEASURES,Sentinel Lymph Node Biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Bilateral mammography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Doppler Ultrasound,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Imaging
DIAGNOSES,Incisional biopsy - action,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasound examination,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Puncture biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Digital mammography,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Imaging
DIAGNOSES,Biopsy,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Biopsy,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Mammography,contralateral breast cancer,0.0,Female Breast Cancer,Imaging
DIAGNOSES,Biopsy of skin procedure,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Contrast enhanced spectral mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Biopsy,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Punch biopsy (procedure),Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Positron Emission Mammography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
DIAGNOSES,Biopsy of skin procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mass Screening,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Early Diagnosis
MEASURES,Genetic screening method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
MEASURES,Doppler Ultrasound,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Puncture biopsy,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
MEASURES,Biopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Orbital biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy of skin procedure,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Genetic screening method,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Genetic Screening,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Biopsy,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Incisional biopsy - action,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Specimen mammography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Sentinel Lymph Node Biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Contrast-Enhanced Ultrasound,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Needle biopsy procedure,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Screening procedure,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Genetic screening method,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Punch biopsy (procedure),Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Contrast enhanced spectral mammography,Multifocal breast carcinoma,0.0,Other,Imaging
DIAGNOSES,Core needle biopsy,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Biopsy of skin procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Core needle biopsy,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Mammography,Stage IIIB Breast Carcinoma,0.0,Other,Imaging
DIAGNOSES,Ultrasound elastography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Biopsy,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,B mode ultrasound,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
DIAGNOSES,Fine needle aspiration biopsy,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,buccal smear biopsy procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mammography,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Imaging
DIAGNOSES,Laparoscopy with biopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasound examination,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Imaging
DIAGNOSES,Biopsy of skin procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Endoscopic biopsy,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Needle biopsy procedure,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Screening procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Contrast-Enhanced Mammography,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Imaging
DIAGNOSES,Excision biopsy,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Genetic screening method,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Initial Diagnosis,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Screening for cancer,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Biopsy,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Core needle biopsy,Lobular carcinoma in situ of breast,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Percutaneous Breast Biopsy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasound-Guided Fine-Needle Aspiration,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Contrast-Enhanced Ultrasound,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Imaging
DIAGNOSES,Initial Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Microlaryngoscopy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Early Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrum Analysis, Raman",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Author,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fluorescent in Situ Hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,"Toxicology screen, general",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Microarray Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,CK2,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cytokeratin-8 Staining Method,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,HIGH SENSITIVITY,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Scanning,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Correlation Study,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Lymphography,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,IMMUNOHISTOCHEMICAL,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Medical pathologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,single cell analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,radiologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Treatment Protocols,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Nurses,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Enzyme-Linked Immunosorbent Assay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Platelet Count measurement,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Physicians,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-1 Staining Method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,diagnostic procedure,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Fluorescence Spectroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Radioisotope scan of lymphatic system,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Research Personnel,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Liver Function Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cell marker,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Medical Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,IMMUNOHISTOCHEMICAL,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Total protein measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,diagnostic procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Autoantibody response,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Polymerase Chain Reaction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Image analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Liquid Chromatography Mass Spectrometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Densitometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Radiometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Activated clotting time measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,thermography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Sample analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Flow Cytometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,In Situ Hybridization,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Surgeon,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Lymphocyte Count,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Radionuclide Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Molecular Diagnosis,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Plasma prolactin,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,rapid technique,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,disease stage,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Research Personnel,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,In Situ Hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Anti-thyroid antibody measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,In Situ Hybridization,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,"Glucose-6-phosphate dehydrogenase measurement, quantitative",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunofluorescence,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Soft Agar Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Morphometric analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Morphometric analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Histocytochemistry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoblotting,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunocytochemistry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Radionuclide Imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Flow Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Enzyme Immunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cytology examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Antibody to islet cells of pancreas measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diaphanography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Plasma oestradiol,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Estradiol measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,IMMUNOHISTOCHEMICAL,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic Neoplasm Staging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Self-Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Galactography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Clinical Research,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Spectrum Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Palpation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Enzyme Immunoassay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,IMMUNOHISTOCHEMICAL,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Morphometric analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Lymphography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Chromatography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Radioimmunoassay,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Culture Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Adsorption,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Histocytochemistry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Self-Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Sensitivity test,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Radioisotope scan of lymphatic system,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Image analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoperoxidase Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Preservation, Biological",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Lipids measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Protein profiling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic radiologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Examination of breast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,CALCULATION,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,thermography,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,mutation analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Flow Cytometry,Breast cancer stage II,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,DNA analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,Clinical Research,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Cytometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Antigen assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Differential Diagnosis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,"Spectroscopy, Nuclear Magnetic Resonance",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic radiologic examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Imaging
DIAGNOSES,Immunoradiometric Assays,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cytodiagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Transillumination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Case-Control Studies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,mutation analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Image analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Clinical Trials Data Monitoring Committees,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Polymerase Chain Reaction,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Breast thermography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cytogenetic procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,friend,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,HIGH SENSITIVITY,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Family,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Fluorescent in Situ Hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Endosonography,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,"Blotting, Western",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,HIGH SENSITIVITY,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
MEASURES,Enzyme-Linked Immunosorbent Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Self-Examination,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Technologist NOS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Clinicians,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Pre-surgery evaluation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Microscopy, Immunoelectron",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Magnetic Resonance Imaging,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Chromosome Mapping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Scanning,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,Chromogenic in situ Hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,logistic regression analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Osteopontin Staining Method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Research Personnel,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Electrophoresis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Toxicology screen, general",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Neutralising antibodies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrometry, Mass, Electrospray Ionization",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cancer Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,"Blotting, Western",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Validation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Health Personnel,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Microscopy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Immunocytochemistry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,chromatin immunoprecipitation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Genotype determination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,DNA analysis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Gene Expression Profiling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,"Spectrum Analysis, Mass",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Dot Immunoblotting,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Medical oncologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Dilution,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Weighing patient,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Medical pathologist,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,"Microscopy, Electron, Scanning",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Computed Tomographic Colonography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Liquid Chromatography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Metabolic analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,breast cancer diagnosis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Prostate specific antigen measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Health Personnel,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Blood cadmium measurement,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,DNA analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Differential white blood cell count procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Sequence Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Optical",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Western Blot,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Reader,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Activated clotting time measurement,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,athlete,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Actor,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Enzyme-Linked Immunosorbent Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Spectroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,2D Polyacrylamide Gel Electrophoresis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Western Blot,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,simulation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cell hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Western Blot,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Histology Procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Mapping,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-1 Staining Method,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Fluorescent in Situ Hybridization,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Mapping,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,diagnostic procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Functional assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,endoscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cytokeratin-14 Staining Method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
MEASURES,Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Polymerase Chain Reaction,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Polymerase chain reaction analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Reporter,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Laser Scanning Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Primary Care Physicians,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed, Single-Photon",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Flow Cytometry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Assay,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Author,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Immunophenotyping,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Beck depression inventory,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic tests,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Tumor Burden,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Administrators,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
MEASURES,Fluorescent in Situ Hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Differential Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fluorescent in Situ Hybridization,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Mapping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Serologic tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Chest CT,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Serum estradiol measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunodiagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cell marker,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Magnetic Resonance Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic tests,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Tumor Burden,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Chest imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,genetic analysis,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-2 Staining Method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Palpation,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Serum selenium,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunophenotyping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Enzyme-Linked Immunosorbent Assay,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,student,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Computed Tomographic Colonography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Endoscopy of nose,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Cell marker,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,tomography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Nucleic acid assay,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,IMMUNOHISTOCHEMICAL,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Triple test,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Androgens measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Stereo microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cell hybridization,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Measurement of serum lipid level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Molecular Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Surveillance Consortium,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,"Interview, Psychological",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,In Situ Hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,"Tomography, Emission-Computed",Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
MEASURES,Immunohistochemistry,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Air steward,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Diagnosis, Fluoroscopic",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Blood typing procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Minimum Inhibitory Concentration measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Gene Expression Profiling,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Gene Expression Profiling,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,DNA stability,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Early Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,clonality,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Polymerase Chain Reaction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,breast cancer diagnosis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Quantitative Microscopy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Nucleic acid assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Microarray Analysis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Body mass index procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,COMPUTED,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Medical practitioners NOS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Computerized tomography, 3 dimensional reconstruction",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Medical Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Differential Diagnosis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Caregiver,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Computed Tomographic Colonography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Culture Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Digital Image Analysis,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Medical Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Imaging
DIAGNOSES,"Tomography, Emission-Computed",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Immunohistochemistry,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Gene Expression Profiling,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Pathology procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fluorescent Antibody Technique,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,PET/CT scan,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,BRCA Mutation Analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Contrast-enhanced Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Digital Breast Tomosynthesis,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
MEASURES,one-step nucleic acid amplification,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectroscopy, Fourier Transform Infrared",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Pathologic Examination,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Psychometrics,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,College of American Pathologists,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Quantitative PCR analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Imaging
MEASURES,Western Blotting,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Digital Breast Tomosynthesis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Computer Assisted Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Lactate dehydrogenase measurement,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion weighted imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Gene Expression Profiling,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,S-Phase Fraction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Count,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Single-Cell Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Medical pathologist,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Laboratory Procedures,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Cell Count,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Microwave Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Surveillance Consortium,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Optical Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Assessment: Cognition,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Papillary carcinoma of the breast,0.0009990009990009,Female Breast Cancer,Biopsy
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
DIAGNOSES,Biomarker Analysis,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Immunohistochemistry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,thermal imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic resonance imaging of breast,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Dermatologist,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Body mass index procedure,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Imaging
DIAGNOSES,tomosynthesis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Radioisotope scan of bone,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Microscopy,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Laboratory Procedures,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Methionine measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Multiparametric Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion weighted imaging,contralateral breast cancer,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion weighted imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Lymphangiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Clinician,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic resonance imaging of breast,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Formalin-Fixed Paraffin-Embedded,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Parametric Image,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Laboratory Procedures,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,High-B-Value Diffusion-Weighted Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Transient elastography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Single-Cell Analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Cell phenotype determination procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Microscopy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic resonance imaging of breast,contralateral breast cancer,0.0,Female Breast Cancer,Biopsy
MEASURES,Colorimetric Cell Viability Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fibrinogen to Albumin Ratio Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Upstaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,PET/CT scan,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Research Personnel,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Subtyping,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,PET/CT scan,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic resonance imaging of breast,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,radiologist,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion weighted imaging,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Immunophenotyping,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,"Ultrasonography, Mammary",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
MEASURES,Study,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Electrocorticogram,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Early Diagnosis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Laboratory Procedures,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
MEASURES,Ultrasonography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Health Personnel,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Microarray Analysis,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Biomarker Analysis,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,tomography,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Carcinoma breast stage I,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Contrast-enhanced Magnetic Resonance Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Computed Tomography (CT) of Liver,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectroscopy, Fourier Transform Infrared",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Fecal analysis procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Fibrin-fibrinogen split products assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,fMRI,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Infrared Thermography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunophenotyping,Luminal B Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Biopsy
DIAGNOSES,Multiparametric Magnetic Resonance Imaging,contralateral breast cancer,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Absolute Reticulocyte Count,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Single-Cell Analysis,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Single-Cell Analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic resonance imaging of breast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Count,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mass Spectrometry,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Laboratory Procedures,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Imaging Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Digital Image Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Research Personnel,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Digital Image Analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Volume Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,PET/CT scan,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Platelet hematocrit measurement,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Photoacoustic Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,T2 (Observed)-Weighted Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Subtyping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Radionuclide Imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,clonality,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,mutation analysis,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoprecipitation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunofluorescence,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Cytokeratin-18 Staining Method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Logistic Regression,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Hair zinc,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Western Blot,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Homocysteine level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Iodine uptake,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,DERIVED,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Functional Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,White Blood Cell Count procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,angiogram,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Xeroradiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrum Analysis, Raman",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic Neoplasm Staging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Immunocytochemistry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Estrogen receptor assay (ERA),Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,"Spectrum Analysis, Raman","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrum Analysis, Raman","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Cloning, Molecular",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Microdissection,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoperoxidase Techniques,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Image analysis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Nucleic acid assay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Mediastinoscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Surgeon,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Estrogen receptor assay (ERA),Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Staining method,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Progesterone receptor assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Morphometric analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,histological diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Early Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,DNA chemical synthesis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,General Practitioners,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diaphanography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Clinical Trials,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,histological diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Carbohydrate antigen 549 measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Radioimmunodetection,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Spectrometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Lymphography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Venography - procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,thermography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic radiologic examination,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
DIAGNOSES,Radioisotope scan of bone,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Chromatography, Affinity",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-1 Staining Method,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-2 Staining Method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Optical Methods,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,DIRECT ASSAY,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Surgeon,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Sequence Determinations,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Estrogen measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Voluntary Workers,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Skeletal X-ray,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Pilot,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Enzyme Immunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Nuclear medicine procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Research Personnel,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-2 Staining Method,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Woman,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Enzyme Immunoassay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,mutation analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-1 Staining Method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Hormone measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Creatinine clearance measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Count,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,"Ultrasonography, Doppler, Color",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
DIAGNOSES,Oncologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,WORK UP,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Histocytochemistry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,genetic analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,"Tomography, Spiral Computed",Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,small angle X ray scattering,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
DIAGNOSES,immunological status,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Plasma insulin,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,HIGH SENSITIVITY,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Colposcopy,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,high throughput analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Exploration with a probe,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Hepatitis B virus DNA assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Plasma estradiol measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Weighing patient,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Gene Expression Profiling,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrum Analysis, Mass","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Abdomen scan,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,molecular imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Patients,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Pathologist evaluation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Insulin-like growth factor binding protein 3 level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Plain x-ray,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Morphometric analysis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Clinicians,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Laboratory studies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,"Tomography, Emission-Computed",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Cell marker,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Ultrasonography,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,HIGH SENSITIVITY,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Clinicians,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Gene Expression Profiling,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
DIAGNOSES,CD4/CD8 ratio procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Provider,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,AIDS diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,mutation analysis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Medical oncologist,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Microscopy, Confocal",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunology profile,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Hemoglobin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic radiologic examination,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,IMMUNOHISTOCHEMICAL,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Hospital specialist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Lymph Node Mapping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Toxicology screen, general",Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,HercepTest,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Plastic surgeon,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,intravital microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Ultrasonography, Doppler, Color",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
MEASURES,Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Patients,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Estimator,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,BREAST.FINE NEEDLE,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Nurses,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Palpation,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
MEASURES,Clinical Trials,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Toxicology screen, general",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Histology Procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic Neoplasm Staging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Autopsy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Immunophenotyping,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
MEASURES,Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cancer antigen 27.29,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,tomography,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Osteopontin Staining Method,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Cytokeratin-14 Staining Method,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Immunophenotyping,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,breast cancer diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Ultrasonic",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic radiologic examination,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed",Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Scanning,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Pulmonary function tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Molecular Diagnostic Testing,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Cell hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Teacher,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Amino acid level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Multimodal Imaging,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Cell marker,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Microscopy, Scanning Tunneling",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Flow Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Sodium measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,HIGH SENSITIVITY,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,rapid diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,proteomic profiling,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,"Sequence Analysis, RNA",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Endocrine studies,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Social Aspects of Cancer,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Principal Investigator,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Attending,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Bone density scan,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Examination of breast,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Sodium measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Computed Tomographic Colonography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,tomography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
MEASURES,explanation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,IMMUNOHISTOCHEMICAL,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Cell marker,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,breast cancer diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Histology Procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Gynecologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,diagnostic procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Estimator,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,X-Ray Computed Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Hematocrit procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectroscopy, Near-Infrared",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-2 Staining Method,Mucinous breast cancer,0.0009990009990009,Other,Biopsy
MEASURES,Interview,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Early Diagnosis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Toxicology screen, general",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Steroid hormone measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Professional guide,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,tailor,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Multimodal Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cone-Beam Computed Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,scholar,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cytological Techniques,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,Immunohistochemistry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Positron Emission Tomography and Magnetic Resonance Imaging,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Consultant surgeon,Stage III Breast Cancer AJCC v6,0.0,Other,Biopsy
DIAGNOSES,Mammogram - symptomatic,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,saliva analysis,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Cytological Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,professional occupation status,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Computer Assisted Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,nipple discharge cytology,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Clinician,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Imaging
DIAGNOSES,Differential panel,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Western Blotting,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Transient elastography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Contrast used,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Scientific Study,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrum Analysis, Raman",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biopsy
MEASURES,Immunohistochemistry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Assay of volatiles,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Chest CT,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Western Blot,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
DIAGNOSES,Magnetic Resonance Spectroscopy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Serum gamma-glutamyl transferase measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Alpha tumour necrosis factor measurement,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Count,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
MEASURES,Real-Time Polymerase Chain Reaction,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Chemokine (C-X3-C Motif) Ligand 1 Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Activation Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Transient elastography,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Pre-surgery evaluation,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Scientific Study,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,electrical impedance tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Medical practitioner,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Dual-Energy X-Ray Absorptiometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Tumor Burden,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Microarray Analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed",Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Imaging
DIAGNOSES,Pre-surgery evaluation,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Pathologic Examination,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Epidermal Growth Factor Receptor Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Conventional Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
MEASURES,Reverse Transcriptase Polymerase Chain Reaction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,fluid aspiration,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Self-Examination,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Work-up,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Ultrasonography, Mammary",Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Superb microvascular imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Health Personnel,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Nuclear magnetic resonance imaging brain,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,"Diagnosis, clinical",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Observation - diagnostic procedure,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
MEASURES,Modeling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Epidermal Growth Factor Receptor Measurement,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Complete Blood Count,Unilateral Breast Carcinoma,0.0,Female Breast Cancer,Biopsy
MEASURES,Magnetic Resonance Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Imaging Reporting and Data System,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Formalin-Fixed Paraffin-Embedded,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Biological Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Digital Image Analysis,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Imaging
DIAGNOSES,Monocyte Chemotactic Protein 1 Measurement,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Clinician,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Count,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,contralateral breast cancer,0.0,Female Breast Cancer,Imaging
DIAGNOSES,Vasoactive intestinal polypeptide measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Oncologists,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Imaging
DIAGNOSES,Cryopreservation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Computational analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Mutation Detection,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Blood glucose measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Genetic Variation Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Hematoxylin and eosin stain method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Androgens measurement,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,breast imaging studies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cytokeratin-18 Staining Method,Carcinoma in situ of breast,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Medical pathologist,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Polymerase Chain Reaction,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Plasma oestrogen,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,X-Ray Computed Tomography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Calcium measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biopsy
DIAGNOSES,Cytogenetic procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,"Cloning, Molecular",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Serum prolactin,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Electron Microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Woman,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Electron Microscopy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Professional Organization or Group,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Antibody to islet cells of pancreas measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Immunodiffusion,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Karyometry,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Silver Staining,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Fluoroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Lymphocyte subset measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Plasma lipid measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Thoracoscopy,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,"Spectroscopy, Nuclear Magnetic Resonance",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Ultrasonography, Interventional",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic radiologic examination,Tubular breast cancer,0.0009990009990009,Other,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Antigen test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fractionation,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Hormone measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Venography - procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Serum prolactin,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,Cell Count,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Medical Imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Histology Procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,"Toxicology screen, general",Carcinoma in situ of breast,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Polarographic measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,tissue processing,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,CALCULATION,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Leukocyte Adherence Inhibition Test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Zinc measurement,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Research Personnel,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biopsy
DIAGNOSES,Serum C reactive protein level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Hematology procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mutagenicity Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Image Cytometry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,PO2 measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,HercepTest,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Triple test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed, Single-Photon",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Surveillance Consortium,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Prostate specific antigen measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,tomography,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-1 Staining Method,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Cytotoxicity assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,HercepTest,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Parathyroid scintigraphy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Provider,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Physical activity assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fluorescent in Situ Hybridization,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Oncology Group,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Molecular Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,High density lipoprotein measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,radiologist,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Faculty,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Immunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Research Personnel,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,molecular imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,TELOMERE ANALYSIS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Sequence Analysis, DNA",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cancer Diagnosis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Serum testosterone measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Blood Count, Complete",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Flow Cytometry,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Preservation, Biological",Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,IMMUNOHISTOCHEMICAL,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Chromogenic in situ Hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,DNA ploidy analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoblot Analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,mutation analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Serum protein profile,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Blood Count, Complete",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Surveillance Consortium,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Genetic Marker Expression,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Surgeon,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion weighted imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Primary Care Physicians,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Tissue Fixation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Flow Cytometry,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Serum estradiol measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Subrenal Capsule Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,HIGH SENSITIVITY,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Radionuclide Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Optical",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Cell marker,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Digital slit-beam radiograph,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Immunohistochemistry,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,histological diagnosis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Infertility study,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Histocytochemistry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Clinical Trials Cooperative Group,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,"Tomography, Spiral Computed",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Blotting, Western",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Spectrum Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Vascular assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Staff,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Employee,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,tomography,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
MEASURES,Mass Fragmentography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunofluorescence,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Drug measurement,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoblot Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Clinical Research,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Statistician,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Maker NOS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Family investigation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,MRI of breast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Body mass index procedure,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Perfusion Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,environmental factors,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Statistical Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Oxygen measurement, partial pressure, arterial",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Microarray Analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed",Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Oncologist,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Radiation therapist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Whole Body Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Medical Imaging,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Paraffin Embedding,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Spinal Puncture,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Biological Assay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Transmission imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,CD4/CD8 ratio procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoassay method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,X-Ray Computed Tomography,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Chemokine (C-X-C Motif) Ligand 10 Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Airway Resistance Test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Western Blotting,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,High sensitivity,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diffuse Optical Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Oncologists,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,MammaPrint,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Pathologic Examination,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Blood Vessel Density,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Axillary Reverse Mapping,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,BRCA Mutation Analysis,contralateral breast cancer,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic Neoplasm Staging,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Computed Tomography with Contrast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Complete Blood Count,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,serum Fatty acid level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,High-Throughput Nucleotide Sequencing,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Noninvasive Prenatal Testing,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,methodological quality,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Assay,Mucinous breast cancer,0.0009990009990009,Other,Biopsy
DIAGNOSES,Physicians,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Estimated Glomerular Filtration Rate,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Chest imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic resonance imaging of breast,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Glomerular Filtration Rate,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,thermography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Fas Cell Surface Death Receptor Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
MEASURES,Risk Analysis,contralateral breast cancer,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Cardiac monitoring,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,PET/CT scan,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,PET/CT scan,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Observation - diagnostic procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Observation - diagnostic procedure,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Cytokeratin 19 Fragment 21-1 Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Elasticity Imaging Techniques,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Lymphangiography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,contralateral breast cancer,0.0,Female Breast Cancer,Biopsy
MEASURES,Nested Case-Control Studies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Pathologic Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Diffusion Kurtosis Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Subtyping,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Foundation for the Accreditation of Cellular Therapy,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Physicians,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Biomarker Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Practitioner,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Positron Emission Tomography and Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
MEASURES,Laboratory Procedures,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoenzyme Procedure,Carcinoma breast stage I,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,High resolution,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Epidermal Growth Factor Receptor Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mutagenesis Procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrum Analysis, Raman",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,PD-L1 IHC 22C3 PharmDx,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Image quality analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Radionuclide Imaging,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Flow Cytometry,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Conventional Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Traditional Healer,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Clinical Decision-Making,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Risk Analysis,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer,Biopsy
MEASURES,Cell Migration Assays,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Count,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Single-Cell Analysis,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Molecular Imaging,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed",malignant neoplasm of breast staging,0.0,Female Breast Cancer,Imaging
DIAGNOSES,Staining Intensity,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Luminal B Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Biopsy
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
DIAGNOSES,"Ultrasonography, Mammary",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Polysomnography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breast scan,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Photon Counting Computed Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fluorescent in Situ Hybridization,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Immunofluorescence,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Paraffin Embedding,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Endoscopy of stomach,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Polymerase Chain Reaction,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic Imaging,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Polymerase Chain Reaction,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Clinical Research,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Centrifugation, Density Gradient",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Staining method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Cortisol measurement, free, urine",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,"Spectrum Analysis, Raman",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Autoradiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Histology Procedure,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Image analysis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Gel Electrophoresis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cytometry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,"Electrophoresis, Agar Gel",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Physical breast examination,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Immunologic Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoperoxidase Techniques,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,"Immune complex assay, Raji cell",Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Cytophotometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Radioimmunoassay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,Flow Cytometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Calcium measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Carcinoembryonic antigen measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Periodic acid Schiff stain method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Measurement of serum lipid level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Estrogen measurement, urine",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fractionation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Radiography, Thoracic",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Sex hormone binding globulin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Radioligand Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,G-Banding,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Tumor marker measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Blood albumin,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Insurance broker,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Serum copper,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,"Autoradiography, Quantitative",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Chromosome Mapping,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Polymerase Chain Reaction,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biopsy
DIAGNOSES,Staining method,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,Reverse Transcriptase Polymerase Chain Reaction,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Oncology Group,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Immunoassay, quantitative",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Metyrapone test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Transillumination,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
MEASURES,Medical Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Free thyroxine index test,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Lymphocyte Count,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Polymerase chain reaction analysis,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biopsy
DIAGNOSES,In Situ Hybridization,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
MEASURES,Fluorescent in Situ Hybridization,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Clinical Research,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Sampling of lymph nodes NOS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Artist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,DNA ploidy analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Clinical oncologist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Ultrasonography,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Electrophoresis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Immunocytochemistry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Serum vitamin D measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Insulin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Urine level measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Differential Diagnosis,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,tomography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Magnetic Resonance Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Scanning,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breath Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,research,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Eosinophil count procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Monocyte count procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Diagnosis, Computer-Assisted",Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
MEASURES,Homologous Recombination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Smooth Muscle Actin Staining Method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Routine chest X-ray,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Quantitative Reverse Transcriptase PCR,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
MEASURES,Positron-Emission Tomography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,"Diagnosis, Computer-Assisted",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,disease stage,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,"Blood Count, Complete",Contralateral breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Plasma prolactin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,CALCULATION,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Symptom checklist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,member,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,DNA analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-2 Staining Method,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Computed radiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,IMMUNOHISTOCHEMICAL,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion Magnetic Resonance Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Co-Immunoprecipitation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Radionuclide Imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,WORK UP,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Ultrasonography, Doppler","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Imaging
DIAGNOSES,Polymerase Chain Reaction,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
MEASURES,Magnetic Resonance Imaging,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Woman,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Spectroscopy,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Latex Fixation Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Physicist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Plasma arginine measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,QUICK METHOD,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,"Physicians, Women",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Genotype determination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Body mass index procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Breast surgeon,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Creatinine clearance measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Diffusion weighted imaging,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Clinical Decision-Making,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Microarray Analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Family Study,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immune Checkpoint Functional Assay,Luminal B Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Biopsy
DIAGNOSES,Coculture Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Study,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Gene Expression Profiling,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Quantitative Reverse Transcriptase PCR,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Body mass index procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Iron binding capacity measurement,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,radiologist,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,S-Phase Fraction,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Multiparametric Magnetic Resonance Imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Imaging
DIAGNOSES,Diagnostic Neoplasm Staging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Cell phenotype determination procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Molecular Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,FLT-Positron Emission Tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Imaging
DIAGNOSES,Monocyte Chemotactic Protein 1 Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Imaging Reporting and Data System,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Imaging
DIAGNOSES,Terahertz Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Count,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,PET/CT scan,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Cytological Techniques,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Patients,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,New Target Lesion Identification,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Contrast-enhanced Magnetic Resonance Imaging,Multifocal breast carcinoma,0.0,Other,Imaging
DIAGNOSES,Near-Infrared Fluorescence Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Wire-Guided Localization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Circulating Tumor Cell Count,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion weighted imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Psychometrics,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Functional assessment,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Body mass index procedure,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Count,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Measurement of serum amino acid level,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,thermal imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,"Microscopy, Phase-Contrast",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Diagnosis,Unilateral Breast Carcinoma,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Gene Expression Profiling,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Single Photon Emission Computed Tomography Computed Tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
MEASURES,Prospective Studies,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Point-of-Care Testing,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Medical pathologist,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,"Alpha-1-fetoprotein measurement, serum",Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Sonographer,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Conventional Imaging,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Digital Breast Tomosynthesis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,Diagnosis,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonic Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Imaging
DIAGNOSES,Cell Count,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Count,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion weighted imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion weighted imaging,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Survivors,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunophenotyping,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
MEASURES,Ultrasonography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Tumor Burden,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Automated count,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,screen techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Complete Blood Count,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,"Microscopy, Fluorescence",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Vitamin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,mutation analysis,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Scientist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fibrinogen assay,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,enzyme linked immunospot assay,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, X-Ray",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Early Diagnosis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Engineer,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,proteomic profiling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Study Section,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,"Angiography, Digital Subtraction",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Oral Glucose Tolerance Test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Oxygen measurement, partial pressure, arterial",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Plasma oestrogen,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Plasma thyroid stimulating hormone,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Tissue culture,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Whole Body Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Semen liquefaction,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,"Copper measurement, serum",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,northern hybridization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Calcium measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Surveys,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Plasma alkaline phosphatase NOS,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Sequence Analysis, DNA",Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biopsy
DIAGNOSES,Plasma zinc measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,breast cancer diagnosis,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Autopsy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Lymphocyte subset measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Serial scanning,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Image Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Infrared photography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Blood count,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,rapid technique,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
MEASURES,Film Dosimetry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-1 Staining Method,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Writer,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Microdissection,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Separation,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Immunology procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Ultrasonography, Doppler",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Image Cytometry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Autoradiography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Sensitivity test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Zinc measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Medical oncologist,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,HIGH SENSITIVITY,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Chromosome analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Histocytochemistry,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Intravenous digital subtraction angiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,mutation analysis,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biopsy
DIAGNOSES,Restriction fragment length polymorphism analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Histocytochemistry,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Image Cytometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Surface Enhanced Laser Desorption Ionization Mass Spectrometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Endocrine function test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Flow Cytometry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Obstetrician,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Radioisotope scan of bone,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Research Personnel,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Magnetic Resonance Spectroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Microdissection,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Mass Fragmentography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cell marker,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoassay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,fiber optic microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Gene Expression Profiling,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,TELOMERE ANALYSIS,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Medical pathologist,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Sample analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Biotinylation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Magnetic Resonance Imaging,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Observers,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Radioimmunoassay,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Radioisotope scan of lymphatic system,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,blood flow measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Urine ratio,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Dual-Energy X-Ray Absorptiometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,MICROSCOPIC COUNT,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Scanning,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Free prostate-specific antigen,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Optical",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Anesthesiologist,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,MANUAL COUNT,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Gene Expression Profiling,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Albumin/Globulin ratio,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Tumor Burden,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,Radionuclide Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed",Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Blotting, Western",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,Western Blot,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,fluorodeoxyglucose positron emission tomography,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Imaging
DIAGNOSES,Tumor Burden,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Histocytochemistry,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Medical Imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Image analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Case Manager,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,genetic analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Body mass index procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,"Diagnosis, Computer-Assisted",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunology profile,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Image analysis, quantitative",HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Light microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Positron Emission Tomography and Magnetic Resonance Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
MEASURES,Quantitative Reverse Transcriptase PCR,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Intravital Microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed",Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Radioisotope scan of bone,Breast cancer stage II,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Echocardiography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic tests,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,"Ethics Committees, Research",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Functional assessment,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,internal-external locus of control scale,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,chromatin immunoprecipitation,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Seeding,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Microscopy,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Estimated Glomerular Filtration Rate,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,PET/CT scan,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Platelet Count measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,serum estrogen,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Pathologic Examination,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Therapeutic evaluation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,High-B-Value Diffusion-Weighted Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Coculture Techniques,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Count,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Transmission Electron Microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Polymerase chain reaction analysis,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Observation - diagnostic procedure,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Surgeon,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed, Single-Photon",Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,Contrast used,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Imaging
DIAGNOSES,Assay,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrum Analysis, Raman",Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Red Blood Cell Count measurement,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Superb microvascular imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Workers,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Optical Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Conventional Imaging,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Decalcification Technique,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoenzyme Procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Positron Emission Tomography and Magnetic Resonance Imaging,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Plasminogen measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Subtyping,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Microbial susceptibility tests,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
MEASURES,Gene Expression Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Subtyping,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Dental Assistants,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Imaging
DIAGNOSES,Gene Expression Profiling,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Foundation for the Accreditation of Cellular Therapy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Chemical Exchange Saturation Transfer Magnetic Resonance Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Separation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Laboratory Procedures,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion Tensor Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,CA 15-3 measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Chemosensitivity Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Organism type determination procedure,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Chromosome Banding,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Low ionic strength saline,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,"Toxicology screen, general","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Indirect Immunofluorescence,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Serum oestrogen,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Image Cytometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Serum zinc,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Bone Marrow Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,IMMUNOHISTOCHEMICAL,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Carbohydrate antigen 549 measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Enzyme Tests,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Light microscopy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Dermatoglyphics,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Internist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,tomography,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,"Radiography, Thoracic",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Serum cholinesterase,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Microscopy, Phase-Contrast",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
DIAGNOSES,Tumor Stem Cell Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Research Design,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Bone marrow scintigraphy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Karyotype determination procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Radioisotope study of liver,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Copper measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Breast X-ray,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Chromosome analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,southern hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,mutation analysis,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Quantitative Microscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,tomography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,comparative genomic analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Immunophenotyping,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Tissue culture,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Free thyroxine index test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,comparative genomic analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonic guidance procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Cell phenotype determination procedure,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
MEASURES,Testing,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Quantitative sensory test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Immunohistochemistry,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,"Protein concentration, test strip measurement",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Polymerase Chain Reaction,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,tissue processing,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,"Ethics Committees, Research",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Cytology procedure,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Ultrasonography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,infrared spectroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,RNA Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Focus Groups,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Professional Organization or Group,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,comparative genomic analysis,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Beta Catenin Staining Method,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Image analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrometry, Mass, Electrospray Ionization","Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,X-Ray Diffraction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,MANUAL COUNT,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Pseudothrombocytopenia,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,IMMUNOHISTOCHEMICAL,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Sentinel Lymph Node Mapping,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Lymph Node Mapping,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Silver Staining,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Whole-Body Scintigraphy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mammogram - localization,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoblotting,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,General surgeon,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Faculty, Medical",Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,radiologist,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Drug measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Polymerase chain reaction analysis,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Chemosensitivity Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Breast Self-Examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Differential Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoradiometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,diagnostic procedure,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Mucin-2 Staining Method,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion weighted imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,Clinical Research,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Surgeon,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Fluorescent in Situ Hybridization,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Cancer Diagnosis,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biopsy
DIAGNOSES,"Imaging, Three-Dimensional",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic Imaging,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,bilateral breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
MEASURES,Multiphoton Microscopy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,Immunohistochemistry,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Radionuclide Imaging,Stage IIA Breast Carcinoma,0.0,Other,Biopsy
DIAGNOSES,Cell Count,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Scientific Study,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,BRCA Mutation Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Real-Time Polymerase Chain Reaction,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Estimated Glomerular Filtration Rate,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,contralateral breast cancer,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Cytological Techniques,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Breast Cancer Type 1 Susceptibility Protein Measurement,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Patients,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
MEASURES,Colorimetric Cell Viability Assay,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
MEASURES,Psychometrics,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Elasticity Imaging Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,MRI brain procedure,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Tumor Burden,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Alanine measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic Imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed",Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrafast MRI,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Attendants -- group,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Lymphocyte to C-Reactive Protein Ratio Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Subtyping,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
MEASURES,Consensus Clustering,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Absolute lymphocyte count,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,medical diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunophenotyping,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Imaging
DIAGNOSES,CA 125 measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,tomography,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,X-Ray Computed Tomography,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Conventional Imaging,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Work-up,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Examination of breast,Invasive Ductal Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Positron Emission Tomography and Magnetic Resonance Imaging,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Imaging
DIAGNOSES,Protein Expression Analysis,estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,community leader,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Multiphoton Microscopy,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,"Physical Therapist - Electrophysiology, Clinical",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Imaging
DIAGNOSES,Diagnostic assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Early Diagnosis,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Biochemical test,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Image Cytometry,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Physicians,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Scintiphotography,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Radioisotope scan of bone,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,Histocytochemistry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Progesterone measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Nucleic acid analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Indium Scan,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Radioimmunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Gel Electrophoresis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,Radioimmunoassay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,HEART STUDY,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Histology Procedure,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Carcinoembryonic antigen measurement,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Cell Culture Techniques,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,In Situ Hybridization,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,"Microscopy, Confocal, Laser Scanning",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Geneticist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Physicians,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Western Blot,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Glomerular Filtration Rate,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,DNA chemical synthesis,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Diagnostic assessment,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,enzyme linked immunospot assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Microscopy, Video",Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Radionuclide Imaging,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Liquid Chromatography Mass Spectrometry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Policy Makers,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Spectrum Analysis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Pharmacokinetic study,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Optical Coherence",Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Miller,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,"Transport Media,",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Blood Count, Complete",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Microscopic observation,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
MEASURES,"Diagnosis, Computer-Assisted",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,D-lactate measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Light microscopy,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Human papillomavirus DNA detection,Sporadic Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biopsy
MEASURES,Liquid Chromatography Mass Spectrometry,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
MEASURES,Assay,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,fluorodeoxyglucose positron emission tomography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Lobular carcinoma in situ of breast,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Immunofluorescence,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Morphometric analysis,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Sampling of lymph nodes NOS,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Cytokeratin-14 Staining Method,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Consultant,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Spiral Computed",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Palpation,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Clinicians,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Karyotype determination procedure,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Cytokeratin-14 Staining Method,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Interleukin level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Image analysis, quantitative",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Plastic surgeon,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Polymerase Chain Reaction,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Optical Coherence",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Magnetic Resonance Imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,spatial data analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,tomography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,neuroimaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,C-reactive protein measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Chest physician,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Exercise stress test,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,diagnostic procedure,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Community Workers,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Liquid Chromatography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Smooth Muscle Actin Staining Method,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Nucleic acid assay,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Activated clotting time measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Electrophoretic Mobility Shift Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Family member,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Blotting, Western",Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Occupational physician,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Imaging
DIAGNOSES,Sequence Analysis,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Image Study,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Radioisotope scan of bone,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
MEASURES,Prosigna Breast Cancer Prognostic Gene Signature Assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Near-Infrared Fluorescence Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic resonance imaging of breast,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Complement C1q binding,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Autoradiography,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Microarray Analysis,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Oncologists,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Imaging
DIAGNOSES,3D COMPUTERIZED TOMOGRAPHY,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunohistochemistry,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Chemokine (C-X-C Motif) Ligand 10 Measurement,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,radiologist,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,High resolution,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Microarray Analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Mutagenesis Procedure,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,In Vivo Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Imaging
DIAGNOSES,MRI Scans,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoglobulin G Subclass 4 Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Oncologists,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,DNA Maintenance,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Digital Breast Tomosynthesis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Imaging
DIAGNOSES,heart study,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Seeding,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Orbital B scan,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Alpha tumour necrosis factor measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,"Microscopy, Atomic Force",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Assay,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Chiropractor,Recurrent Breast Carcinoma,0.0019980019980019,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Immunologic Techniques,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Laboratory Procedures,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,HER2-negative breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Computer assisted method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Embedding,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Cell function assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ki67 Measurement,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Whole body bone imaging (procedure),Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Biological Assay,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,High resolution,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,CA 125 measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Plasma lipid measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Reflection illumination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Carcinoma breast stage I,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,digital tomosynthesis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,"Tomography, Emission-Computed",HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,PET/CT scan,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Nurses,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
MEASURES,Assay,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Merging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Observation - diagnostic procedure,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Image Study,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic resonance imaging of breast,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Differential panel,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Spinal Puncture,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,CA 19-9 measurement,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Serum protein electrophoresis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Serum prolactin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,RAPID TEST,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Study Section,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Neutralization,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Steroid activity,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Immunoblotting,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Plasma calcitonin level,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Estrogen receptor assay (ERA),Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Serum selenium measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Radioisotope scan of lymphatic system,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Physical assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Densitometry,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,C1q binding assay,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Morphometric analysis,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Serum ferritin measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,End Point,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Serum cholesterol measurement,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,thermography,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Microscopy,Ductal Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,southern hybridization,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Specimen collection,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Serum riboflavine measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,two-dimensional electrophoresis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Morphometric analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,"Protein concentration, test strip measurement",Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Radiographic imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,comparative genomic analysis,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Drug measurement,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Prostate specific antigen measurement,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Tumor marker measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Comparative Genomic Hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Anti-SS-B antibody,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Electrophoresis, Polyacrylamide Gel",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Reverse Transcriptase Polymerase Chain Reaction,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Multimodal Imaging,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
MEASURES,"Spectrum Analysis, Mass",Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Sequence Analysis,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Chromogenic in situ Hybridization,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Mean cell hemoglobin measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Tissue Array Analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,thermography,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Author,Carcinoma in situ of breast,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Health Personnel,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Committee Members,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Reader,Breast cancer stage III,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,"Spectrum Analysis, Mass",Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Family investigation,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Oncologist,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
DIAGNOSES,Dermatoglyphics,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Spectrum Analysis,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Interferometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Midwife,Familial cancer of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Cytokeratin-8 Staining Method,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Enzyme-Linked Immunosorbent Assay,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Chest imaging,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,American,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Spectrum Analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,single cell analysis,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Examination of breast,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Pharmacokinetic study,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Cytophotometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Oncologist,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Autoantibody measurement,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion weighted imaging,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Clinicians,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Diffusion Magnetic Resonance Imaging,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,endoscopy,Breast cancer metastatic,0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Employer,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Carcinoma of Male Breast,0.0059940059940059,Male Breast Cancer,Biopsy
DIAGNOSES,Tumor Burden,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,"Ultrasonography, Mammary",Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
MEASURES,univariate analysis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Ultrasonography, Doppler",Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
MEASURES,Random Allocation,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Scanning,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,CA 15-3 measurement,Breast cancer recurrent,0.0069930069930069,Recurrent Breast Cancer,Biopsy
MEASURES,Fluorescent in Situ Hybridization,"Carcinoma, Ductal, Breast",0.0139860139860139,Female Breast Cancer,Biopsy
DIAGNOSES,Nuclear magnetic resonance imaging whole body,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Clinical Research,Contralateral breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Physical breast examination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,WORK UP,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Breast Self-Examination,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
MEASURES,Gene Expression Profiling,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,medical specialist,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Phase contrast,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Imaging
DIAGNOSES,Cell Count,Breast cancer invasive NOS,0.0269730269730269,Female Breast Cancer,Biopsy
DIAGNOSES,Nutrition Assessment,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,The Cancer Genome Atlas,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Caregiver,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Biopsy
MEASURES,Differential panel,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
MEASURES,Computer Assisted Diagnosis,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fatty Liver Index,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Infrared spectroscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Complete Blood Count,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,tomography,Breast cancer stage II,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Positron-Emission Tomography,Breast cancer stage II,0.0,Female Breast Cancer,Imaging
DIAGNOSES,Author,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Magnetic Resonance Imaging,Breast cancer stage II,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Reporter (occupation),Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Laboratory Procedures,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
MEASURES,Assay,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Pyrosequencing,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Arginine measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mammogram - symptomatic,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Red Cell Fatty Acid Profile,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Laboratory Procedures,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Monocyte count procedure,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Electrophysiology studies,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Quantitative PCR analysis,Inflammatory Breast Carcinoma,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,T4 free measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Fluorescent Antibody Technique,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Laparoscopy,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Red cell distribution width determination,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrasonography,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Chef,Female Breast Carcinoma,0.0069930069930069,Female Breast Cancer,Biopsy
DIAGNOSES,Gate-keeper,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
MEASURES,Data Collection,contralateral breast cancer,0.0,Female Breast Cancer,Biopsy
DIAGNOSES,Nucleic acid sequencing,"Breast Cancer, Familial",0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Clinician,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Body mass index procedure,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
MEASURES,"Tomography, Optical Coherence",Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Mass Spectrometry,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Transient elastography,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Sulfate measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnosis,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Biopsy
MEASURES,Study,Breast Carcinoma,0.0509490509490509,Female Breast Cancer,Biopsy
DIAGNOSES,Leukemia Inhibitory Factor Measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Radioisotopic Labeling (lab procedure),Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Examination by method,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Early Diagnosis
DIAGNOSES,Multimodal Imaging,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Fluorescence Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Restriction Spectrum Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,"Tomography, Emission-Computed",estrogen receptor-positive breast cancer,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Electroporation,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,Pegylation,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Serum Triglyceride Measurement,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
MEASURES,Statistical Technique,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Methionine measurement,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography and Computed Tomography Scan,Metastatic Breast Carcinoma in the Skin,0.0,Other,Biopsy
DIAGNOSES,Diagnosis,Basal-Like Breast Carcinoma,0.0019980019980019,Female Breast Cancer,Biopsy
DIAGNOSES,Diffuse Optical Imaging,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Clinician,Early-Stage Breast Carcinoma,0.0029970029970029,Female Breast Cancer,Biopsy
DIAGNOSES,Substance Abuse Detection,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
MEASURES,Magnetic resonance imaging of breast,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Histological Techniques,Primary malignant neoplasm of breast with axillary lymph node invasion,0.0,Other,Biopsy
DIAGNOSES,Classic tomography,Carcinoma breast stage IV,0.0209790209790209,Female Breast Cancer,Biopsy
DIAGNOSES,Work-up,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biopsy
DIAGNOSES,Optical Imaging,Secondary malignant neoplasm of breast,0.0049950049950049,Female Breast Cancer,Biopsy
DIAGNOSES,Patient Navigators,Malignant neoplasm of breast,0.2177822177822178,Female Breast Cancer,Biopsy
DIAGNOSES,Ultrafast MRI,Noninfiltrating Intraductal Carcinoma,0.0389610389610389,Female Breast Cancer,Biopsy
DIAGNOSES,Diagnostic Imaging,Triple Negative Breast Neoplasms,0.0179820179820179,Female Breast Cancer,Biopsy
DIAGNOSES,Transient elastography,HER2-positive carcinoma of breast,0.0059940059940059,Female Breast Cancer,Biopsy
DIAGNOSES,FDG-Positron Emission Tomography,Locally advanced breast cancer,0.0019980019980019,Female Breast Cancer,Imaging
DIAGNOSES,Multiparametric Magnetic Resonance Imaging,Luminal B Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Biopsy
